Effects of Insulin in Relatives of Patients with Type 1 Diabetes Mellitus
The DOI matches its Crossref record; 39 of the 39 references it cites were found in a registry or an index.
Abstract
BACKGROUND: It is unknown whether insulin therapy can delay or prevent diabetes in nondiabetic relatives of patients with diabetes. METHODS: In a randomized, controlled, nonblinded clinical trial, we screened 84,228 first-degree and second-degree relatives of patients with diabetes for islet-cell antibodies; 3152 tested positive; 2103 of the 3152 underwent genetic, immunologic, and metabolic staging to quantify their risk; 372 of the 2103 had a projected five-year risk of more than 50 percent; 339 of the 372 (median age, 11.2 years) were randomly assigned to undergo either close observation or an intervention that consisted of low-dose subcutaneous ultralente insulin, administered twice daily for a total dose of 0.25 unit per kilogram of body weight per day, plus annual four-day continuous intravenous infusions of insulin. Oral glucose-tolerance tests were performed every six months. Median follow-up was 3.7 years. The primary end point was a diagnosis of diabetes. RESULTS: Diabetes was diagnosed in 69 subjects in the intervention group and 70 subjects in the observation group. The annualized rate of progression to diabetes was 15.1 percent in the intervention group and 14.6 percent in the observation group. The cumulative incidence of diabetes was similar in the two groups (relative risk in the intervention group as compared with the observation group, 0.96). Most subjects in whom diabetes developed were asymptomatic. Progression to diabetes occurred at a faster rate among subjects with abnormal base-line glucose tolerance (22 percent per year) than among those with normal base-line glucose tolerance (10 percent per year, P<0.001). There were no episodes of severe hypoglycemia. The incidence of chemical hypoglycemia, assessed without ascertainment bias, was similar in the two groups. CONCLUSIONS: In persons at high risk for diabetes, insulin at the dosage used in this study does not delay or prevent type 1 diabetes.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“but subgroup analyses suggested a benefit of oral insulin in individuals with the highest titres of insulin auto-antibodies.142,143”
From Type 1 diabetes (2018) · cites this paper as [142]
In the citing paper
“The Diabetes Prevention Trial—Type 1, tested whether oral or parental insulin prevented the development of type 1 diabetes in people who were autoantibody positive. Neither approach reduced diabetes development,”
From Type 1 diabetes (2018) · cites this paper as [142]
In the citing paper
“If one islet autoantibody is found, the test should be repeated and the other autoantibodies should be assayed because the risk of type 1 diabetes increases if two or more autoantibodies are positive (443).”
From Guidelines and Recommendations for Laboratory Analysis in the Diagnosis and Management of Diabetes Mellitus (2023) · cites this paper as [443]
In the citing paper
“Subcutaneously or intranasally delivered insulin was found to have no preventive effects.39,48”
From The future of type 1 diabetes therapy (2025) · cites this paper as [48]
In the citing paper
“Risk can be assessed by islet cell autoantibodies alone, without the need for evaluating endogenous insulin reserves, as was done for the U.S. DPT-1 trial (306).”
From Guidelines and recommendations for laboratory analysis in the diagnosis and management of diabetes mellitus (2011) · cites this paper as [306]
1 more claim about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus
The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus (1997) · Diabetes Care · doi:10.2337/diacare.20.7.1183 · Cited by 6,220
The Pathogenesis of Insulin-Dependent Diabetes Mellitus
Epstein, F. H., Atkinson, M. A., & Maclaren, N. K. (1994) · New England Journal of Medicine · doi:10.1056/nejm199411243312107 · Cited by 1,078
Verge, C. F., Stenger, D., Bonifacio, E., Colman, P. G., Pilcher, C., Bingley, P. J., & Eisenbarth, G. S. (1998) · Diabetes · doi:10.2337/diabetes.47.12.1857 · Cited by 420
Cognitive Deficits in Adolescents Who Developed Diabetes Early in Life
Ryan, C., Vega, A., & Drash, A. (1985) · Pediatrics · doi:10.1542/peds.75.5.921 · Cited by 413
Insulitis and Diabetes in NOD Mice Reduced by Prophylactic Insulin Therapy
Atkinson, M. A., Maclaren, N. K., & Luchetta, R. (1990) · Diabetes · doi:10.2337/diab.39.8.933 · Cited by 299
Insulin prophylaxis in individuals at high risk of type 1 diabetes
Keller, R. J., Jackson, R. A., Eisenbarth, G. S., & Eisenbarth, G. (1993) · The Lancet · doi:10.1016/0140-6736(93)91215-8 · Cited by 298
Pugliese, A., Gianani, R., Moromisato, R., Awdeh, Z. L., Alper, C. A., Erlich, H. A., Jackson, R. A., & Eisenbarth, G. S. (1995) · Diabetes · doi:10.2337/diab.44.6.608 · Cited by 207
Gotfredsen, C. F., Buschard, K., & Frandsen, E. K. (1985) · Diabetologia · doi:10.1007/bf00703140 · Cited by 205
Vardi, P., Dib, S. A., Tuttleman, M., Connelly, J. E., Grinbergs, M., Radizabeh, A., Riley, W. J., Maclaren, N. K., Eisenbarth, G. S., & Soeldner, J. S. (1987) · Diabetes · doi:10.2337/diab.36.11.1286 · Cited by 192
Attentional Functioning in Children and Adolescents With IDDM
Rovet, J., & Alvarez, M. (1997) · Diabetes Care · doi:10.2337/diacare.20.5.803 · Cited by 153
Cited by
Items 501–600 of 832
Trudeau, J. D., Chandler, T. M., Soukhatcheva, G., Verchere, C. B., & Tan, R. (2007) · Diabetologia · doi:10.1007/s00125-007-0600-9 · Cited by 10
Type 1 Diabetes as a Model for Prediction and Diagnosis
Lernmark, Å. (2004) · Autoimmunity · doi:10.1080/08916930410001726012 · Cited by 11
Editorial: Prevention in Child Health Psychology and the Journal of Pediatric Psychology
Tercyak, K. P. (2007) · Journal of Pediatric Psychology · doi:10.1093/jpepsy/jsm089 · Cited by 10
Abolo, L., Ssenkaali, J., Mulumba, O., & Awe, O. I. (2024) · Frontiers in Genetics · doi:10.3389/fgene.2024.1353081 · Cited by 9
Felton, J. L., Cuthbertson, D. D., WARNOCK, M. V., Lohano, K., Meah, F. A., Wentworth, J. M., Sosenko, J. M., Evans‐Molina, C., & for the Type 1 Diabetes TrialNet Study Group (2021) · Diabetologia · doi:10.1007/s00125-021-05573-6 · Cited by 10
Bashan, E., & Hodish, I. (2012) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2012.03.012 · Cited by 9
Management of Diabetes in Children
Wolfsdorf, J. I., & Garvey, K. C. (2015) · Elsevier eBooks · doi:10.1016/b978-0-323-18907-1.00049-4 · Cited by 13
Have we pushed the needle for treatment of Type 1 diabetes?
Naushad, N., Perdigoto, A. L., Rui, J., & Herold, K. C. (2017) · Current Opinion in Immunology · doi:10.1016/j.coi.2017.09.004 · Cited by 9
Sperling, M. A., Wolfsdorf, J. I., Menon, R. K., Tamborlane, W. V., Maahs, D. M., Battelino, T., & Phillip, M. (2021) · Elsevier eBooks · doi:10.1016/b978-0-323-62520-3.00021-x · Cited by 13
Immunotherapy Trials for Type 1 Diabetes: The Contribution of George Eisenbarth
Skyler, J. S., & Pugliese, A. (2013) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2013.0107 · Cited by 9
Yamada, S., Irie, J., Shimada, A., Kodama, K., Morimoto, J., Suzuki, R., Oikawa, Y., & Saruta, T. (2003) · Autoimmunity · doi:10.1080/0891693031000079266 · Cited by 10
Genetics for targeting disease prevention: diabetes
Newell, A. (2004) · Primary Care Clinics in Office Practice · doi:10.1016/j.pop.2004.04.002 · Cited by 10
Research charting a course for evidence‐based clinical dietetic practice in diabetes
Delahanty, L. M. (2010) · Journal of Human Nutrition and Dietetics · doi:10.1111/j.1365-277x.2010.01065.x · Cited by 13
Islet cell-associated autoantibodies in Ethiopians with diabetes mellitus
Siraj, E. S., Gupta, M. K., Yifter, H., Abdela, A. A., Kebede, T., Reja, A., & Abdulkadir, J. (2016) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2016.05.005 · Cited by 10
A Question of Tolerance—Antigen-Specific Immunotherapy for Type 1 Diabetes
Naranjo, J. D. L., Bergot, A., Buckle, I., & Hamilton‐Williams, E. E. (2020) · Current Diabetes Reports · doi:10.1007/s11892-020-01363-3 · Cited by 10
Xu, P., Qian, X., Schatz, D., Cuthbertson, D. D., Krischer, J. P., & the DPT-1 Study Group (2014) · Diabetes Care · doi:10.2337/dc13-2603 · Cited by 9
Arai, T., Moriyama, H., Shimizu, M., Sasaki, H., Kishi, M., Okumachi, Y., Yasuda, H., Hara, K., Yokono, K., & Nagata, M. (2010) · Clinical Immunology · doi:10.1016/j.clim.2010.02.016 · Cited by 9
Regulatory T cells in autoimmune endocrine diseases
Wong, F. S., & Dayan, C. M. (2008) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2008.07.007 · Cited by 11
Misso, M. L., O’Connor, D. A., Egberts, K. J., & Shaw, J. E. (2005) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd005103 · Cited by 9
Type 1 Diabetes—Reaping the Rewards of a Targeted Research Investment
FRADKIN, J. E., Wallace, J. A., Akolkar, B., & Rodgers, G. P. (2016) · Diabetes · doi:10.2337/db15-1030 · Cited by 9
Atkinson, M. A. (2016) · Elsevier eBooks · doi:10.1016/b978-0-323-29738-7.00032-0 · Cited by 16
Ismail, H. M., Evans‐Molina, C., DiMeglio, L. A., Becker, D. J., Libman, I. M., Sims, E. K., Boulware, D. C., Herold, K. C., Rafkin, L. E., Skyler, J. S., et al. (2019) · Pediatric Diabetes · doi:10.1111/pedi.12845 · Cited by 9
Targeting Lymphoid Tissues to Promote Immune Tolerance
Chen, X. Y., Du, G. S., & Sun, X. (2021) · Advanced Therapeutics · doi:10.1002/adtp.202100056 · Cited by 9
Enfermedades autoinmunitarias asociadas a diabetes mellitus tipo 1A
Ferreira‐Hermosillo, A., & Molina-Ayala, M. (2015) · Revista médica de Chile · doi:10.4067/s0034-98872015000800012 · Cited by 8
Clinical Potential of Antigen-Specific Therapies in Type 1 Diabetes
Coppieters, K. T., Hansen, B. S., & von Herrath, M. G. (2012) · The Review of Diabetic Studies · doi:10.1900/rds.2012.9.328 · Cited by 8
Metabolic syndrome – Removing roadblocks to therapy: Antigenic immunotherapies
Coppieters, K. T., & von Herrath, M. G. (2014) · Molecular Metabolism · doi:10.1016/j.molmet.2013.12.005 · Cited by 10
Hao, W., Greenbaum, C. J., Krischer, J. P., Cuthbertson, D. D., Marks, J. B., & Palmer, J. P. (2015) · Diabetes Care · doi:10.2337/dc14-1825 · Cited by 8
Grönholm, J., & Lenardo, M. J. (2014) · Clinical Immunology · doi:10.1016/j.clim.2014.11.007 · Cited by 8
The Main Events in the History of Diabetes Mellitus
Goldman, R., Zajac, J., Shrestha, A., Patel, P., & Poretsky, L. (2017) · Springer eBooks · doi:10.1007/978-3-319-18741-9_1 · Cited by 10
The Ethics of Type 1 Diabetes Prediction and Prevention Research
Ross, L. F. (2003) · Metamedicine · doi:10.1023/a:1024686511111 · Cited by 11
Kahn, S. E. (2004) · Seminars in Cell and Developmental Biology · doi:10.1016/j.semcdb.2004.02.005 · Cited by 9
Research navigating the course of clinical practice in diabetes
Delahanty, L. M., & Nathan, D. M. (2004) · Journal of the American Dietetic Association · doi:10.1016/j.jada.2004.09.028 · Cited by 9
Sacks, D. B. (2012) · Tietz Textbook of Clinical Chemistry and Molecular Diagnostics · doi:10.1016/b978-1-4160-6164-9.00046-9 · Cited by 7
Evans‐Molina, C., Dor, Y., Lernmark, Å., Mathieu, C., Millman, J. R., Mirmira, R. G., Pociot, F., REDONDO, M. J., Rich, S. S., Richardson, S. J., et al. (2025) · Diabetes · doi:10.2337/dbi25-0011 · Cited by 9
Penaforte-Saboia, J. G., Couri, C. E. B., Albuquerque, N. V., Linard, L. L. P., Araújo, D. M. P. A., de Oliveira, S., Gomes, T., Pinheiro, M. M., Castelo, M. H. D. C. G., Fernandes, V. O., et al. (2024) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s437635 · Cited by 8
Greenbaum, C. J., Nepom, G. T., Heickman, L. K. W., Wherrett, D. K., DiMeglio, L. A., Herold, K. C., & Krischer, J. P. (2024) · Diabetes · doi:10.2337/dbi24-0020 · Cited by 8
Immune biomarkers in immunotherapeutic trials for type 1 diabetes: Cui prodest?
Čulina, S., & Mallone, R. (2012) · Diabetes & Metabolism · doi:10.1016/j.diabet.2012.05.005 · Cited by 8
Lindbladh, I., Svärd, A. A., & Lernmark, Å. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-812102-3.00041-5 · Cited by 8
Simmons, K. M., Alkanani, A. K., McDaniel, K. A., Goyne, C., Miao, D., Zhao, Z., Yu, L., & Michels, A. W. (2016) · PLoS ONE · doi:10.1371/journal.pone.0166213 · Cited by 7
Ismail, H. M., Becker, D. J., Libman, I. M., Herold, K. C., REDONDO, M. J., Atkinson, M. A., Cleves, M. A., Palmer, J. P., Sosenko, J. M., & Diabetes Prevention Trial‐Type 1 (DPT‐1) Study Group (2020) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13982 · Cited by 7
Self-citationPrevention of Type 1 Diabetes Mellitus
Pozzilli, P., & Guglielmi, C. (2009) · Springer eBooks · doi:10.1007/978-0-387-09841-8_49 · Cited by 7
Autoimmune diabetes: More than just one flavor?
Chiu, H. K., & Palmer, J. P. (2004) · Journal of Endocrinological Investigation · doi:10.1007/bf03345296 · Cited by 8
A clinical research network in diabetes for the UK
Heller, S. R., & Kinmonth, A. L. (2004) · Diabetic Medicine · doi:10.1111/j.1464-5491.2004.01503.x · Cited by 7
The Disposition Index in Autoantibody-Positive Individuals at Risk for Type 1 Diabetes
Ismail, H. M., Cuthbertson, D. D., Galderisi, A., Libman, I. M., Jacobsen, L. M., Moran, A., Petrelli, A., Atkinson, M. A., REDONDO, M. J., Hannon, T. S., et al. (2025) · Diabetes · doi:10.2337/db24-1000 · Cited by 6
Type 1 diabetes mellitus—a door opening to a real therapy?
Chatenoud, L. (2011) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2011.148 · Cited by 6
Feature ranking based on synergy networks to identify prognostic markers in DPT-1
Adl, A. A., Qian, X., Xu, P., Vehik, K., & Krischer, J. P. (2013) · EURASIP Journal on Bioinformatics and Systems Biology · doi:10.1186/1687-4153-2013-12 · Cited by 6
Sims, E. K., Cuthbertson, D. D., Felton, J. L., Ismail, H. M., Nathan, B. M., Jacobsen, L. M., Paprocki, E. L., Pugliese, A., Palmer, J. P., Atkinson, M. A., et al. (2022) · Diabetes Care · doi:10.2337/dc22-1362 · Cited by 6
Decreased Core Temperature and Increased β 3 -Adrenergic Sensitivity in Diabetes-Prone BB Rats
Åkesson, L., Hawkins, T., Jensen, R. A., Fuller, J. M., Breslow, N. E., & Lernmark, Å. (2007) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2006.0036 · Cited by 6
Novel Gene Associations in Type 1 Diabetes
Ilonen, J., & Hermann, R. (2010) · Current Diabetes Reports · doi:10.1007/s11892-010-0133-3 · Cited by 6
Corcos, N., Čulina, S., Deligne, C., Lavaud, C., You, S., & Mallone, R. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.616215 · Cited by 7
T cell targeted immunotherapy for autoimmune disease
Lee, E. H., & Sinha, A. A. (2005) · Autoimmunity · doi:10.1080/08916930500418136 · Cited by 6
World Diabetes Day: Perspectives on immunotherapy of Type 1 Diabetes
Chatenoud, L. (2015) · European Journal of Immunology · doi:10.1002/eji.201570114 · Cited by 7
Type 1 Diabetes in Youth and Technology-Based Advances in Management
Ferber, C., Mao, C. S., & Yee, J. K. (2020) · Advances in Pediatrics · doi:10.1016/j.yapd.2020.04.002 · Cited by 8
Incorporating Type 1 Diabetes Prevention Into Clinical Practice
Gregory, J. M., Lilley, J. S., Misfeldt, A. A., Buscariollo, D. L., Russell, W. E., & Moore, D. J. (2010) · Clinical Diabetes · doi:10.2337/diaclin.28.2.61 · Cited by 6
Type 1 Diabetes Mellitus: Epidemiology, Genetics, Pathogenesis, and Clinical Manifestations
Ali, O. (2009) · Springer eBooks · doi:10.1007/978-0-387-09841-8_12 · Cited by 11
Type 1 Diabetes in the Child and Adolescent /
Haller, M. J., Silverstein, J. H., & Rosenbloom, A. L. (2006) · CRC Press eBooks · doi:10.3109/9781439808948-10 · Cited by 6
Donelan, W., Wang, H., Li, S., Pittman, D. L., Li, Y., Han, S., Sun, Y., Carter, C., Atkinson, M. A., Reeves, W. H., et al. (2013) · Europe PMC (PubMed Central) · Cited by 7
Diabetes Issues in Women and Children
Bloomgarden, Z. T. (2003) · Diabetes Care · doi:10.2337/diacare.26.8.2457 · Cited by 9
Disease prevention with islet autoantigens
Eisenbarth, G. S., & Jasinski, J. (2004) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2003.12.005 · Cited by 6
Natural Evolution, Prediction, and Prevention of Type 1 Diabetes in Youth
Taplin, C. E., & Barker, J. M. (2008) · Endocrine Research · doi:10.1080/07435800802080328 · Cited by 6
Psychotropic-Induced Weight Gain: Liability, Mechanisms and Treatment Approaches
McIntyre, R. S., Konarski, J. Z., & Keck, P. E. (2006) · CRC Press eBooks · doi:10.3109/9780849374517.014 · Cited by 6
Type 1 Diabetes — Does Suppressing T Cells Increase Insulin?
Lernmark, Å. (2005) · New England Journal of Medicine · doi:10.1056/nejme058114 · Cited by 8
Relationship between T and B Cell Responses to Proinsulin in Human Type 1 Diabetes
Durinovic‐Belló, I., MAISEL, N., Schlosser, M., Kalbacher, H., Deeg, M., EIERMANN, T. H., Karges, W., & Boehm, B. O. (2003) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1288.045 · Cited by 6
Desai, S. M., Kashalikar, P., Sanap, A. P., Shekatkar, M., & Bhonde, R. R. (2022) · Recent Advances in Inflammation & Allergy Drug Discovery · doi:10.2174/2772270817666221122103029 · Cited by 5
Parenteral insulin suppresses T cell proliferation to islet antigens
Greenbaum, C. J., McCulloch‐Olson, M., Chiu, H. K., Palmer, J. P., & Brooks‐Worrell, B. (2010) · Pediatric Diabetes · doi:10.1111/j.1399-5448.2010.00674.x · Cited by 5
Immunomodulatory agents and cell therapy for patients with type 1 diabetes
Rodacki, M., Silva, K. R., Araújo, D. B., Dantas, J. R., Ramos, M. E. N., Zajdenverg, L., & Baptista, L. S. (2024) · Archives of Endocrinology and Metabolism · doi:10.20945/2359-4292-2024-0233 · Cited by 6
Anita, L. I., & Ho, T. C. (2011) · JBI Library of Systematic Reviews · doi:10.11124/01938924-201109481-00022 · Cited by 11
Diabetes Clinical Trials: What Is New at NIDDK?
FRADKIN, J. E. (2004) · Clinical Diabetes · doi:10.2337/diaclin.22.3.109 · Cited by 5
Raffel, L. J., & Goodarzi, M. O. (2013) · Elsevier eBooks · doi:10.1016/b978-0-12-383834-6.00090-2 · Cited by 6
Beyan, H., & Leslie, R. D. G. (2007) · Humana Press eBooks · doi:10.1007/978-1-59745-517-6_12 · Cited by 5
Prevention of Type 1 Diabetes: Current Perspective
Pande, A. K., Dutta, D., & Singla, R. (2023) · Indian Journal of Endocrinology and Metabolism · doi:10.4103/ijem.ijem_78_23 · Cited by 6
Lester, L. B. (2005) · Humana Press eBooks · doi:10.1385/1592599001 · Cited by 6
Hypoglycemia in the Toddler and Child
Wolfsdorf, J. I., & Stanley, C. A. (2021) · Elsevier eBooks · doi:10.1016/b978-0-323-62520-3.00023-3 · Cited by 6
NEW THERAPIES AIMED AT THE PRESERVATION OR RESTORATION OF BETA CELL FUNCTION IN TYPE 1 DIABETES
Keymeulen, B. (2006) · Acta Clinica Belgica · doi:10.1179/acb.2006.047 · Cited by 6
Insulin: a critical autoantigen and potential therapeutic agent in Type 1 diabetes
Pugliese, A. (2006) · Expert Review of Clinical Immunology · doi:10.1586/1744666x.2.3.419 · Cited by 6
Prophylactic Insulin Treatment of Syngeneically Transplanted Pre-diabetic BB-DP Rats
Sparre, T., Sprinkel, A. M. E., Christensen, U. B., Karlsen, A. E., Pociot, F., & Nerup, J. (2003) · Autoimmunity · doi:10.1080/0891693031000079248 · Cited by 5
Inverse vaccination with islet autoantigens to halt progression of autoimmune diabetes
Hinke, S. A. (2011) · Drug Development Research · doi:10.1002/ddr.20488 · Cited by 5
Sperling, M. A., WEINZIMER, S. A., & Tamborlane, W. V. (2008) · Elsevier eBooks · doi:10.1016/b978-141604090-3.50015-6 · Cited by 5
β-cell regeneration to treat Type 1 diabetes mellitus
Eduardo, C., Foss‐Freitas, M. C., Foss, M. C., & Voltarelli, J. C. (2007) · Expert Review of Endocrinology & Metabolism · doi:10.1586/17446651.3.1.51 · Cited by 6
Rhodes, E. T., Wolfsdorf, J. I., Cuthbertson, D. D., Feldman, H. A., Ludwig, D. S., & the DPT-1 Study Group (2005) · Diabetes Care · doi:10.2337/diacare.28.8.1948 · Cited by 5
The changing faces of diabetes
Hirsch, I. B. (2003) · Primary Care Clinics in Office Practice · doi:10.1016/s0095-4543(03)00031-9 · Cited by 5
Peralta, F. G., Pinés-Corrales, P. J., Santos, E., Cuesta, M., Albarrán, O. G., Azriel, S., Castaño, L. A., Mathieu, C., & on behalf of the AGORA Diabetes Collaborative Group (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14020418 · Cited by 5
Emerging drugs for the treatment of type 1 diabetes mellitus: a review of phase 2 clinical trials
Min, T., & Bain, S. C. (2023) · Expert Opinion on Emerging Drugs · doi:10.1080/14728214.2023.2188191 · Cited by 4
Targeting the Trimolecular Complex: The Pathway Towards Type 1 Diabetes Prevention
Michels, A. W. (2013) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2013.0114 · Cited by 4
Besenhard, M. O., Jarzabek, M. A., O’Farrell, A. C., Callanan, J. J., Prehn, J. H. M., Byrne, A. T., & Huber, H. J. (2016) · Journal of Theoretical Biology · doi:10.1016/j.jtbi.2016.04.028 · Cited by 4
Zhao, L. P., Carlsson, A., Larsson, H. E., Forsander, G., Ivarsson, S. A., Kockum, I. S., Ludvigsson, J., Marcus, C., Persson, M., Samuelsson, U., et al. (2017) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.2921 · Cited by 4
Beta‐cell activity and development of Type 1 diabetes
Thea, R., & Buschard, K. (2024) · Apmis · doi:10.1111/apm.13441 · Cited by 4
Challenges to Reshape the Future of Type 1 Diabetes Research
Bleich, D., & Wagner, D. H. (2018) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2018-00568 · Cited by 4
Prevention of type 1 diabetes: where we are and where we are going
Frontino, G., GUERCIO, N. S., SCARAMUZZA, A., D’ANNUNZIO, G., Toni, S., CITRINITI, F., & Bonfanti, R. (2021) · Minerva Pediatrics · doi:10.23736/s2724-5276.21.06529-0 · Cited by 4
Diagnostik, Therapie und Verlaufskontrolle des Diabetes mellitus im Kindes- und Jugendalter
Neu, A., Bürger-Büsing, J., Danne, T., Dost, A., Holder, M., Holl, R. W., Holterhus, P., Kapellen, T. M., Karges, B., Kordonouri, O., et al. (2021) · Der Diabetologe · doi:10.1007/s11428-021-00769-1 · Cited by 5
Animal Models for Study of Diabetes Mellitus
Lukačínová, A., Hubková, B., Rácz, O., & Nistiar, F. (2013) · InTech eBooks · doi:10.5772/48325 · Cited by 7
Insulin-specific vaccination for type 1 diabetes: a step closer?
Harrison, L. C. (2012) · Human Vaccines & Immunotherapeutics · doi:10.4161/hv.19673 · Cited by 4
Update on Global Intervention Studies in Type 1 Diabetes
Chiang, J. L., Haller, M. J., & Schatz, D. (2012) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2012.07.003 · Cited by 4
Prediction and prevention of type 1 diabetes mellitus: initial results and recent prospects
Madácsy, L. (2011) · Orvosi Hetilap · doi:10.1556/oh.2011.29246 · Cited by 6
Aspects cliniques et diagnostiques du diabète de l'enfant
Bouhours‐Nouet, N., & Coutant, R. (2011) · EMC - Pédiatrie - Maladies infectieuses · doi:10.1016/s1637-5017(11)72493-0 · Cited by 7
The Immunoendocrinopathy Syndromes
Barker, J. M., Anderson, M. S., & Gottlieb, P. A. (2016) · Elsevier eBooks · doi:10.1016/b978-0-323-29738-7.00040-x · Cited by 5
Pathophysiology of Type 1 Diabetes
Meneghini, L. (2007) · CRC Press eBooks · doi:10.3109/9780849326233-2 · Cited by 4
Immunoendocrinopathy syndromes
Scherbaum, W., & Schott, M. (2011) · doi:10.1093/med/9780199235292.003.0195 · Cited by 4
Lambert, P. F., & Bingley, P. J. (2006) · Medicine · doi:10.1383/medc.2006.34.2.47 · Cited by 4
Yamada, K., Moriyama, H., Okumachi, Y., Arai, T., Kameno, M., Kishi, M., Yasuda, H., Hara, K., Yokono, K., & Nagata, M. (2008) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1447.006 · Cited by 4
Metadata
- Authors
- Diabetes Prevention Trial–Type 1 Diabetes Study Group
- Affiliations
- University of Miami (US)
- Corresponding author
- Diabetes Prevention Trial–Type 1 Diabetes Study Group
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2002-05-30
- Volume
- 346
- Issue
- 22
- Pages
- 1685-1691
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W614574849
- Cited by
- 836
- References
- 30
- Citations by year
- 2026: 9 · 2025: 22 · 2024: 24 · 2023: 21 · 2022: 20 · 2021: 32 · 2020: 21 · 2019: 21 · 2018: 22 · 2017: 27 · 2016: 26 · 2015: 34 · 2014: 30 · 2013: 38 · 2012: 42
- FWCI
- 28.81
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institute of Diabetes and Digestive and Kidney Diseases (UC4DK117009)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Diabetes and associated disorders
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pancreatic function and diabetes
- Keywords
- type 1 diabetes, insulin therapy, diabetes prevention, relatives of diabetic patients, islet cell antibodies, ultralente insulin, continuous intravenous insulin infusion, glucose tolerance, hypoglycemia, disease progression
- MeSH terms
- Adolescent, Adult, Child, Child, Preschool, Diabetes Mellitus, Type 1, Family, Female, Glucose Tolerance Test, Humans, Hypoglycemia, Hypoglycemic Agents, Injections, Subcutaneous, Insulin, Islets of Langerhans, Male, Middle Aged, Risk Factors, Treatment Failure
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.